Long-term SSRI use linked to reduced Alzheimer’s pathology but mixed effects on cognition

Long-term SSRI use linked to reduced Alzheimer’s pathology but mixed effects on cognition

A new study published in Alzheimer’s & Dementia suggests that long-term use of selective serotonin reuptake inhibitors (SSRIs) may reduce biological markers of Alzheimer’s disease, but their influence on cognitive function appears inconsistent. The findings show that individuals with Alzheimer’s who used SSRIs had lower levels of tau protein in the blood and showed restored activity in a brain region typically impaired by the disease. However, t…

SSRIs Restore Brain Function in Alzheimer’s

A new study suggests that SSRIs, commonly prescribed antidepressants, may reduce biological markers of Alzheimer’s disease. In a cohort of 191 individuals, AD patients on SSRIs had lower levels of plasma phosphorylated tau-181, a key indicator of disease severity.